Bioequivalence Study of Neurogabin-M (Gabapentin 400 mg) Capsule With Parketin (Gabapentin 400 mg) Capsules

Inclusion Criteria: * All subjects should be healthy and free from any epidemic, contagious or measurable disease (e.g. Malaria, Dengue) * Age range for inclusion will be 18-50 year. * BMI for all Subjects will be between 18.5-30.0 kg/m2. * Participant capable of understanding the informed consent. * Non Smokers, who have not smoked in last 3 months. * Medical history, physical examination and screening tests must fall in normal range, unless the investigator considers the abnormality to be clinically not significant. * Clinically normal physical findings including ECG and safety laboratory values at the Screening visit and on Day -1 of each treatment period, including negative results for drugs of abuse, breath alcohol, Hepatitis B, Hepatitis C and HIV. * Participants (who can read and understand Urdu) should be able to give informed consent, understand and sign the Informed Consent Form. * Participants should have adequate organ function (i.e., kidney, liver and heart). * All subjects will have urine samples assayed for the presence of drugs of abuse as part of the clinical screening procedures and at each study period check-in. Exclusion Criteria: * Any active allergic disease or a history of any significant allergic disease (e.g. Rhinitis, dermatitis, asthma). * Known hypersensitivity to Investigational drug(s). * Abnormal results of blood and urine tests conducted at screening unless the investigator considers an abnormality to be clinically irrelevant. * Presence or history of cardiac (e.g. Myocardial Infarction, arrythmia), renal (e.g. renal insufficiency) , hepatic (e.g. hepatic impairment) , organ insufficiency, bone marrow disease, hematological abnormality (e.g. leukemia, anemia), photosensitivity, neurological disorders) or gastrointestinal disease known to interfere with the drug absorption, distribution, metabolism or elimination (e.g. dysphagia, dyspepsia). * History or presence of any musculo skeletal disease (e.g. Tendonitis). * Subject donated blood (450ml) within 12 weeks minimum preceding the study. * Alcoholic or with a history of chronic alcohol intake or consumed alcohol or Gutka in last 3 months. * Ingestion of OTC drug, within 14 days of drug administration (e.g. aspirin, ibuprofen). * History of intake of any prescribed medicine (e.g. Captopril, Sumatriptan) during a period of 30 days, prior to drug administration day of study. * Ingestion of investigational drug within 30 days, prior to investigational drug administration in the study. * Ingestion of any known hepatic or renal clearance altering agents (e.g. erythromycin, cimetidine, barbiturates, phenothiazines, etc.) for a period of 30 days, prior to study initiation. Drug interaction section at 5.10 and Warnings section at 5.11 should be considered. * Subjects with an uncontrolled medical condition (i.e., hypertension, cardiac arrhythmias, CHF) that places the patient at risk by participating in the study. * Subjects with known HIV, hepatitis B or C infection or autoimmune diseases. * History of drug exposure which, in the opinion of Investigator, amounts to drug abuse (e.g. Amphetamine). * Participation in other drug studies within three months prior to study initiation. * Subjects who is unable to or likely to be non-compliant with protocol requirements or restrictions. * Limited mental capacity to the extent that the subject is unable to provide legal consent and information regarding the side effects or tolerance of the study drug. * Pregnancy or breast feeding, women of child bearing age who are not using a recognized form of contraception for at least last 30 days or using hormonal contraception, are also excluded.